All In MedTech

Device Trial Radar · NCT01653808

In Vivo Evaluation of the Nipro Elisio™ Dialyzer

Last checked: Nov 20, 2026Latest source record: Sep 14, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Apr 2009

Primary completion

Sep 2012

Study completion Sep 2012

Sponsor

Lead sponsor
Nipro Europe N.V.Not on our public-company list
Sponsor type
Industry
First posted
Jul 31, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and biocompatibility of the Nipro Elisio 210H dialyzer between two dialysis modalities, conventional hemodialysis and on line hemodiafiltration.

Conditions

  • Chronic Kidney Disease

Interventions

  • Elisio-210HDevice

    comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration

  • conventional hemodialysisProcedure

    comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer

  • on line hemodiafiltrationProcedure

    comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pre-dialytic serum beta-2 microglobulin levelTime frame: Month 1 (after one month)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Center

    Montpellier, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.